Sort   by:  
 Page size 
UnknownOvercoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
Not available
S-EPMC3973216 | biostudies-literature
UnknownUtility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients.
Not available
S-EPMC6628062 | biostudies-literature
UnknownDNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients.
Not available
S-EPMC6678219 | biostudies-literature
UnknownCombination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo.
Not available
S-EPMC8834319 | biostudies-literature
UnknownPhase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.
Not available
S-EPMC8048685 | biostudies-literature
UnknownDual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Not available
S-EPMC3913937 | biostudies-literature
UnknownCirculating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.
Not available
S-EPMC9925790 | biostudies-literature
UnknownMining the Plasma Cell Transcriptome for Novel Cell Surface Proteins.
Not available
S-EPMC6121261 | biostudies-literature
UnknownCell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma.
Not available
S-EPMC10480144 | biostudies-literature
Sort   by:  
 Page size